Pipecuronium (bromide)

Pipecuronium bromide is a potent long-acting nondepolarizing steroidal neuromuscular blocking agent (NMBA), and a bisquaternary ammonium compound. Pipecuronium bromide is a powerful competitive nAChR antagonist with a Kd of 3.06 μM[1][2][3][4][5].

Product Specifications

CAS Number

[52212-02-9]

UNSPSC

12352005

Hazard Statement

H300, H312, H331

Target

NAChR

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/pipecuronium-bromide.html

Purity

99.88

Solubility

DMSO : 150 mg/mL (ultrasonic) |H2O : 100 mg/mL (ultrasonic)

Smiles

C[C@@]1([C@H]2OC(C)=O)[C@](C[C@@H]2N3CC[N+](C)(C)CC3)([H])[C@@](CC[C@]4([H])[C@@]5(C[C@H](N6CC[N+](C)(C)CC6)[C@@H](OC(C)=O)C4)C)([H])[C@]5([H])CC1.[Br-].[Br-]

Molecular Formula

C35H62Br2N4O4

Molecular Weight

762.70

Precautions

H300, H312, H331

References & Citations

[1]Tassonyi E, et al. Reversal of Pipecuronium-Induced Moderate Neuromuscular Block with Sugammadex in the Presence of a Sevoflurane Anesthetic: A Randomized Trial. Anesth Analg. 2015 Aug;121 (2) :373-80.|[2]Tassonyi E, et al. Reversal of Deep Pipecuronium-Induced Neuromuscular Block With Moderate Versus Standard Dose of Sugammadex: A Randomized, Double-Blind, Noninferiority Trial. Anesth Analg. 2018 Dec;127 (6) :1344-1350.|[3]Alánt O, et al. First clinical experience with a new neuromuscular blocker pipecurium bromide. Arzneimittelforschung. 1980;30 (2a) :374-9.|[4]Töröcsik A, et al. Characterization of somatodendritic neuronal nicotinic receptors located on the myenteric plexus. Eur J Pharmacol. 1991 Sep 24;202 (3) :297-302.|[5]Kárpáti E, et al. Investigation of neuromuscular blocking agents at Richter Ltd. Acta Pharm Hung. 2002;72 (1) :37-48.